Future Oncology

友情提示：以下期刊信息可能会有更新，仅供参考，请在投稿前自行登录期刊官网仔细核实。

期刊名

Future Oncology

FUTURE ONCOL

ISSN / eISSN

1479-6694 / 1744-8301

目标和范围

Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.

The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.

研究方向

肿瘤学

CiteScore

5.20

查看趋势图

CiteScore 学科排名

类别	分区	排名
Medicine - Oncology	Q2	#155/366
Medicine - Cancer Research	Q3	#124/214

Web of Science 核心合集

Science Citation Index Expanded (SCIE)	Social Sciences Citation Index (SSCI)
Indexed	-

类别 (Journal Citation Reports 2023)	分区
ONCOLOGY - SCIE	Q3

H-index

出版国家或地区

ENGLAND

出版商

Future Medicine Ltd.

出版周期

Monthly

出版年份

2005

年文章数

298

Open Access

通讯方式

FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB

同领域相关热门期刊
近期发表文章

A predictive nomogram developed and validated for gastric cancer patients with triple-negative tumor markers: (2023) Yitian Xu, Pengshan Zhang, Zai Luo, Gang Cen, Shaopeng Zhang, Yuan Zhang, Chen Huang

Addressing environmental pollution and cancer: the imperative of the 2030 agenda: (2023) Rita Bonfiglio, Manuel Scimeca, Alessandro Mauriello

The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results: (2023) Hope S. Rugo, Seock-Ah Im, Anil A. Joy, Yaroslav Shparyk, Janice M. Walshe, Bethany Sleckman, Sherene Loi, Kathy Puyana Theall, Sindy Kim, Xin Huang,...

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer: a plain language summary of the DESTINY-Gastric01 study: (2023) Kohei Shitara

Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up: (2023) Yohann Loriot, Anne O'Hagan, Arlene O Siefker-Radtke

Pralsetinib in patients with RET fusion–positive non-small cell lung cancer: A plain language summary of the ARROW study: (2023) Frank Griesinger, Giuseppe Curigliano, Vivek Subbiah, Christina S Baik, Daniel SW Tan, Dae H Lee, Daniel Misch, Elena Garralda, Dong-Wan Kim, Anthonie...

Residual plasma Epstein–Barr virus DNA after intensity-modulated radiation therapy is associated with poor outcomes in nasopharyngeal carcinoma: (2023) Ping Zhou, Juan Zhou, Chen-Lu Lian, Yi-Feng Yu, Rui Zhou, Qin Lin, San-Gang Wu

Immunotherapy as a later-line option for HER2-altered advanced non-small-cell lung cancer: taxane might be a favorable partner: (2023) Yaning Yang, Guangjian Yang, Weihua Li, Haiyan Xu, Xuezhi Hao, Shuyang Zhang, Xin Ai, Siyu Lei, Yan Wang

Actual situation of decision-making support from medical staff when cancer patients make treatment choices: (2023) Yuko Kawasaki, Kei Hirai, Manabu Nii, Yoshiyuki Kizawa, Atsuko Uchinuno

Analysis of the risk factors of radiation pneumonitis and the predictive ability of dosiomics in non-small-cell lung cancer: (2023) Lei Zhuang, Xue Bai, Ying Chen, Danhong Zhang, Liming Sheng, Xianghui Du

认证评论

注：认证评论选取于全球各个学术评论平台和社交媒体。

The overall speed is quite fast, and the suggestions provided by the reviewers are also very fitting to the content of the article. I can apply for an expedited review. The journal's homepage states that publication is guaranteed within 6 weeks. I thought that if it exceeds 6 weeks, it would not be considered expedited publication. However, the journal editor said that the review process has already been expedited, so the fee still needs to be paid. In the end, when it comes to publication, they also suggested if I want to expedite the production process, which costs an additional $1170. It's really tough for low-income individuals! But at least this expedited production is included in the expedited publication, so it's acceptable.

2022-08-04

Those who are eligible to apply for the expedited review channel can still enjoy a relatively fast overall speed.

2022-01-05

查看所有评论

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.